IMDZ Discontinues SYNOVATE, FDA Delays Decision On ADMA's Bivigam, TRVN Snubbed

Today's Daily Dose brings you news about FDA postponing the decision date on ADMA Biologics' BIVIGAM by 2 months; Immune Design's decision to pull the plug on a phase III study; Corium International getting acquired by a private investment firm; FDA panel voting against approval of Trevena's pain medication Oliceridine, and stock offering of SeaSpine, Iovance and Synthetic Biologics.

from RTT - Biotech https://ift.tt/2yv6qOY
via IFTTT